Bob Baltera is currently a Senior Advisor with the venture firm Frazier Life Sciences and serves on the board of the Frazier portfolio company, Inipharm. Previously he served as Chairman of the Board of Directors for Mavupharma, a Frazier-founded company focused on novel approaches to selectively target the STING (stimulator of interferon genes) pathway, until its acquisition by AbbVie. In addition, Bob was a board member of the Frazier portfolio company Imago, which was acquired by Merck.

Before joining Frazier, Bob was Chief Executive Officer of Amira Pharmaceuticals until its sale to Bristol-Myers Squibb in 2011 for $475 million. Previously, he held several senior management positions for over 17 years at Amgen.

Bob earned his MBA. from the Anderson School at the University of California, Los Angeles; and a BS in microbiology and an MS in genetics from The Pennsylvania State University.